Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Shattuck Labs, Inc. Director's Dealing 2020

Oct 9, 2020

34607_dirs_2020-10-08_1adf45d6-3fff-41bc-8d37-a146208ef879.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Shattuck Labs, Inc. (STTK)
CIK: 0001680367
Period of Report: 2020-10-08

Reporting Person: Pandite Arundathy N. (Chief Medical Officer)

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 100303 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (Right to Buy) $0.01 2027-12-21 Common Stock (5863) Direct
Stock Option (Right to Buy) $2.95 2028-09-18 Common Stock (63705) Direct
Stock Option (Right to Buy) $4.67 2030-08-05 Common Stock (82200) Direct

Footnotes

F1: Includes 16,789 restricted stock units, which will vest in equal monthly installments through July 24, 2021, subject to the Reporting Person's continued service to the Issuer.

F2: This option represents a right to purchase a total of 5,863 shares of the Issuer's common stock, 527 of which have vested, with the remaining shares vesting in equal monthly installments through July 24, 2021, subject to the Reporting Person's continued service to the Issuer.

F3: This option represents a right to purchase a total of 63,705 shares of the Issuer's common stock, 37,161 of which have vested, with the remaining shares vesting in equal monthly installments through May 15, 2022, subject to the Reporting Person's continued service to the Issuer.

F4: This option represents a right to purchase a total of 82,200 shares of the Issuer's common stock, one quarter of which will vest on August 6, 2021, with the remaining three quarters vesting in equal monthly installments through August 6, 2024, subject to the Reporting Person's continued service to the Issuer.